Citalopram as treatment of depression in patients with epilepsy

Luigi M. Specchio, Alfonso Iudice, Nicola Specchio, Angela La Neve, Antonia Spinelli, Renato Galli, Raffaele Rocchi, Monica Ulivelli, Marina De Tommaso, Chiara Pizzanelli, Luigi Murri

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Objectives: To assess the safety of citalopram as a treatment of depression in patients with epilepsy. Methods: This is an open, multicentered, uncontrolled study. Depressed epileptic patients on antiepileptic drugs (AEDs) took part in the study. Patients who had a mild frequency of seizures in the 4 previous months underwent treatment with citalopram (20 mg/d) for 4 consecutive months. A change in seizure frequency from the baseline was chosen as the primary measure for the safety of citalopram and efficacy against depressive symptoms was taken as secondary measure. Depression was rated using the Montgomery-Asberg and Zung depression rating scales. Clinical assessments were performed at baseline, and at 2 and 4 months of citalopram therapy. Results: Forty-five patients were enrolled. Six patients dropped out of the study early: none of them because of a deterioration of seizure frequency. An overall improvement in seizure frequency was observed in the 39 patients who completed the study. Plasma AED concentrations were unchanged during therapy, and depressive symptoms improved markedly. Twenty-two patients complained of adverse effects, mainly headache, nausea, dizziness, somnolence, and fatigue. Conclusions: In this open, multicentered, uncontrolled study, 4 months' of treatment with citalopram (20 mg/d) were associated with an improvement in depressive symptoms and reduction in seizure frequency.

Original languageEnglish
Pages (from-to)133-136
Number of pages4
JournalClinical Neuropharmacology
Volume27
Issue number3
DOIs
Publication statusPublished - May 2004

Fingerprint

Citalopram
Epilepsy
Depression
Seizures
Anticonvulsants
Therapeutics
Safety
Dizziness
Nausea
Fatigue
Headache

Keywords

  • Citalopram
  • Depression
  • Epilepsy
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Specchio, L. M., Iudice, A., Specchio, N., La Neve, A., Spinelli, A., Galli, R., ... Murri, L. (2004). Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology, 27(3), 133-136. https://doi.org/10.1097/00002826-200405000-00009

Citalopram as treatment of depression in patients with epilepsy. / Specchio, Luigi M.; Iudice, Alfonso; Specchio, Nicola; La Neve, Angela; Spinelli, Antonia; Galli, Renato; Rocchi, Raffaele; Ulivelli, Monica; De Tommaso, Marina; Pizzanelli, Chiara; Murri, Luigi.

In: Clinical Neuropharmacology, Vol. 27, No. 3, 05.2004, p. 133-136.

Research output: Contribution to journalArticle

Specchio, LM, Iudice, A, Specchio, N, La Neve, A, Spinelli, A, Galli, R, Rocchi, R, Ulivelli, M, De Tommaso, M, Pizzanelli, C & Murri, L 2004, 'Citalopram as treatment of depression in patients with epilepsy', Clinical Neuropharmacology, vol. 27, no. 3, pp. 133-136. https://doi.org/10.1097/00002826-200405000-00009
Specchio, Luigi M. ; Iudice, Alfonso ; Specchio, Nicola ; La Neve, Angela ; Spinelli, Antonia ; Galli, Renato ; Rocchi, Raffaele ; Ulivelli, Monica ; De Tommaso, Marina ; Pizzanelli, Chiara ; Murri, Luigi. / Citalopram as treatment of depression in patients with epilepsy. In: Clinical Neuropharmacology. 2004 ; Vol. 27, No. 3. pp. 133-136.
@article{02a5b4516e5d451db44d4d9e306aec4e,
title = "Citalopram as treatment of depression in patients with epilepsy",
abstract = "Objectives: To assess the safety of citalopram as a treatment of depression in patients with epilepsy. Methods: This is an open, multicentered, uncontrolled study. Depressed epileptic patients on antiepileptic drugs (AEDs) took part in the study. Patients who had a mild frequency of seizures in the 4 previous months underwent treatment with citalopram (20 mg/d) for 4 consecutive months. A change in seizure frequency from the baseline was chosen as the primary measure for the safety of citalopram and efficacy against depressive symptoms was taken as secondary measure. Depression was rated using the Montgomery-Asberg and Zung depression rating scales. Clinical assessments were performed at baseline, and at 2 and 4 months of citalopram therapy. Results: Forty-five patients were enrolled. Six patients dropped out of the study early: none of them because of a deterioration of seizure frequency. An overall improvement in seizure frequency was observed in the 39 patients who completed the study. Plasma AED concentrations were unchanged during therapy, and depressive symptoms improved markedly. Twenty-two patients complained of adverse effects, mainly headache, nausea, dizziness, somnolence, and fatigue. Conclusions: In this open, multicentered, uncontrolled study, 4 months' of treatment with citalopram (20 mg/d) were associated with an improvement in depressive symptoms and reduction in seizure frequency.",
keywords = "Citalopram, Depression, Epilepsy, Safety",
author = "Specchio, {Luigi M.} and Alfonso Iudice and Nicola Specchio and {La Neve}, Angela and Antonia Spinelli and Renato Galli and Raffaele Rocchi and Monica Ulivelli and {De Tommaso}, Marina and Chiara Pizzanelli and Luigi Murri",
year = "2004",
month = "5",
doi = "10.1097/00002826-200405000-00009",
language = "English",
volume = "27",
pages = "133--136",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Citalopram as treatment of depression in patients with epilepsy

AU - Specchio, Luigi M.

AU - Iudice, Alfonso

AU - Specchio, Nicola

AU - La Neve, Angela

AU - Spinelli, Antonia

AU - Galli, Renato

AU - Rocchi, Raffaele

AU - Ulivelli, Monica

AU - De Tommaso, Marina

AU - Pizzanelli, Chiara

AU - Murri, Luigi

PY - 2004/5

Y1 - 2004/5

N2 - Objectives: To assess the safety of citalopram as a treatment of depression in patients with epilepsy. Methods: This is an open, multicentered, uncontrolled study. Depressed epileptic patients on antiepileptic drugs (AEDs) took part in the study. Patients who had a mild frequency of seizures in the 4 previous months underwent treatment with citalopram (20 mg/d) for 4 consecutive months. A change in seizure frequency from the baseline was chosen as the primary measure for the safety of citalopram and efficacy against depressive symptoms was taken as secondary measure. Depression was rated using the Montgomery-Asberg and Zung depression rating scales. Clinical assessments were performed at baseline, and at 2 and 4 months of citalopram therapy. Results: Forty-five patients were enrolled. Six patients dropped out of the study early: none of them because of a deterioration of seizure frequency. An overall improvement in seizure frequency was observed in the 39 patients who completed the study. Plasma AED concentrations were unchanged during therapy, and depressive symptoms improved markedly. Twenty-two patients complained of adverse effects, mainly headache, nausea, dizziness, somnolence, and fatigue. Conclusions: In this open, multicentered, uncontrolled study, 4 months' of treatment with citalopram (20 mg/d) were associated with an improvement in depressive symptoms and reduction in seizure frequency.

AB - Objectives: To assess the safety of citalopram as a treatment of depression in patients with epilepsy. Methods: This is an open, multicentered, uncontrolled study. Depressed epileptic patients on antiepileptic drugs (AEDs) took part in the study. Patients who had a mild frequency of seizures in the 4 previous months underwent treatment with citalopram (20 mg/d) for 4 consecutive months. A change in seizure frequency from the baseline was chosen as the primary measure for the safety of citalopram and efficacy against depressive symptoms was taken as secondary measure. Depression was rated using the Montgomery-Asberg and Zung depression rating scales. Clinical assessments were performed at baseline, and at 2 and 4 months of citalopram therapy. Results: Forty-five patients were enrolled. Six patients dropped out of the study early: none of them because of a deterioration of seizure frequency. An overall improvement in seizure frequency was observed in the 39 patients who completed the study. Plasma AED concentrations were unchanged during therapy, and depressive symptoms improved markedly. Twenty-two patients complained of adverse effects, mainly headache, nausea, dizziness, somnolence, and fatigue. Conclusions: In this open, multicentered, uncontrolled study, 4 months' of treatment with citalopram (20 mg/d) were associated with an improvement in depressive symptoms and reduction in seizure frequency.

KW - Citalopram

KW - Depression

KW - Epilepsy

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=2942528615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942528615&partnerID=8YFLogxK

U2 - 10.1097/00002826-200405000-00009

DO - 10.1097/00002826-200405000-00009

M3 - Article

C2 - 15190237

AN - SCOPUS:2942528615

VL - 27

SP - 133

EP - 136

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 3

ER -